CRS: HHS’ LDT Policy Shifts Raise Regulatory, Coverage Issues

By Kelly Lienhard / December 14, 2020 at 1:58 PM

The Congressional Research Service says HHS’ decision to remove laboratory-developed tests from FDA oversight yet still require the agency to review voluntarily submitted emergency use authorization requests raises several regulatory and coverage issues.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.